AIO-Studien-gGmbH is a non-profit limited liability company (gGmbH) based in Berlin, Germany, specializing in the management and sponsorship of clinical trials in internal oncology. Founded in 2007 and registered in the commercial register of Berlin-Charlottenburg, it emerged from the study center of the Arbeitsgemeinschaft Internistische Onkologie (AIO) within the Deutsche Krebsgesellschaft e.V. (German Cancer Society).
The organization provides practical support to investigators in the design, implementation, and management of clinical studies. Its team of project managers, coordinators, and assistants handles projects from conception to completion, offering expertise in legal, financial, and scientific matters. Services include GCP-compliant Phase I-IV trials, register studies, quality assurance, monitoring, data analysis, publication support, biometrics consulting, vendor management, and fundraising.
As a subsidiary focused on promoting science and research, AIO-Studien-gGmbH facilitates German and international participation in oncology trials, such as the ATOMIC study on adjuvant treatment for stage III colon cancer. It operates nationally and internationally, bridging investigators, funders, and partners to advance cancer therapies and improve patient care in the field of internal oncology.
Also known as AIO-Studien gGmbH.
None yet. When a new project in the record names AIO-Studien-gGmbH as owner, partner or investor, it shows here.
FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.
